drugset / Trial / NCT03866330
Wharton's Jelly-derived Mesenchymal Stem Cells in Osteoarthritis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase I/II study will enroll 100 subjects with mild to moderate osteoarthritis of the hip/knee/ glenohumeral joint will be enrolled according to strict inclusion and exclusion criteria. Subjects will receive every three months a single dose of at least 10 million of Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) form the Polish Stem Cell Bank for 12 months (maximum four doses in total and at least 40 million of WJMSC in total) via ultrasound guided intra-articular injection.
Timeline
- Start
- 2019-03-01
- Primary completion
- 2019-12
- Completion
- 2022-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Wharton Jelly derived Mesenchymal Stem Cells | Cell therapy | 1e+07 cells | Other |